The pharmaceutical industry has entered the innovation inflection point, and the industry "water seller" has ushered in the development opportunity.

"Pharmaceutical Network Market Analysis" With the volume of procurement, consistent evaluation, new drug approval and evaluation speed up and other good policies, forcing the pharmaceutical industry innovation and upgrading, China's pharmaceutical industry has entered an era of innovation inflection point.
At the same time, the global pharmaceutical innovation is also moving towards the domestic industry transfer, which also gives the pharmaceutical industry "water seller" - CRO enterprises to bring more development opportunities, the future penetration rate of the domestic CRO industry will continue to improve, leading companies scale advantages, industrial chain advantages are expected to continue to strengthen.
For the innovative pharmaceutical industry, the existence of CRO is to help it solve high-risk, high-tech, high-investment, long-term bottlenecks in new drug research and development, reduce the cost of research and development, shorten research and development time, while helping to improve the success rate of research and development, to help products in the current increasingly competitive new drug market has a first-come advantage.
china's pharmaceutical outsourcing ratio is currently about 39.5 per cent and is expected to rise to 49.3 per cent by 2023, according to data released last year.
2019, China's CRO industry is expected to reach $43.2 billion by 2023, with a compound growth rate of about 21.1% in 2019-2023.
on the domestic CRO track, mainly including the drug Mingkangde, Tag Pharmaceuticals, Kailaiying, Zhao Yanxin, Kanglonghuacheng, Tengbo Pharmaceuticals, Kyushua Pharmaceuticals, Pharmaceutical Stone Technology and other competitive enterprises.
Among them, the pharmaceutical Mingkangde industrial chain is relatively complete, involving small molecular drugs preclinical CRO (main business), clinical CRO and small molecular drug CDMO field;
, is involved in small-molecule chemical pharmaceutical CDMO, macro-molecular biopharmaceuticals, and preclinical CRO.
company has the U.S. FDA and European EMEA approval requirements of cGMP and non-cGMP production workshop and high standards of high-live drug production workshop.
Some industry analysts pointed out that by comparing these enterprises' income, net profit, gross margin, net profit margin, net asset return, etc., it is found that the revenue of most key enterprises is about 30% in five years, and the five-year compound growth rate of net profit is more than 40%;
can be seen that the industry is in a high-speed development stage, and pharmaceutical Mingkangde's revenue and net profit scale are the first, worthy of industry attention.
August 13, Drug Mingkang disclosed its 2020 half-yearly report.
the first half of this year, pharmaceutical mingkang's revenue was RMB7,231 million, up 22.68 percent year-on-year, while net profit attributable to shareholders of listed companies was RMB1,717 million, up 62.49 percent year-on-year,
report said.
currently has four business segments, namely: China Laboratory Services, CDMO/CMO Services, U.S. Lab Services, Clinical Research and Other CRO Services.
the first half of 2020, revenue from the four major sectors was RMB3.780 billion, RMB2.162 billion, RMB782 million and RMB 500 million, respectively.
reporting period, its CDMO/CMO service covered more than 1,100 new drug molecules, of which 42 were in Phase III and 26 were approved for market, with 26 MAH projects currently under way, including 4 commercial production projects.
by adopting a "follow the development of drug molecules" business model, the number of drug Mingkangde its small molecule drug CDMO pipeline molecules increased by more than 260.
At the same time, pharmaceutical Mingkangde on the fluid chemistry technology platform, oligonucleotide and peptide drugs CDMO capacity-building, high-active pharmaceutical raw materials production capacity construction, etc. have been upgraded, its new high-activity API laboratory and workshop in Changzhou has been put into production, after Shanghai Jinshan, its second highly active API research and development production base.
announcement, the future drug Mingkang will also increase the development of sterile preparations and clinical drug production and commercial production capacity.
.